SPSandeep T. Patil

Sandeep T. Patil

*This is an algorithmically generated author record based on publicly available information.

Sandeep T. Patil has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • John E. Hale

    Lilly Research Laboratories, MS 1533, Lilly Corporate Center, Indianapolis, Indiana 46285

    2 shared publications
  • Michael D. Knierman

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA

    2 shared publications
  • William Z. Potter

    8008 Seminole Street, Philadelphia, PA 19118, United States

    2 shared publications
  • Alan X. Pan

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, Merck Research Laboratories, West Point, Pennsylvania 19486, Lilly-NUS Centre for Clinical Pharmacology Pte, Ltd., Singapore 117597, and California Clinical Trials, Glendale, California 91206

    1 shared publication
  • Angela Bonner Freeman

    Lilly Research Laboratories, MS 1533, Lilly Corporate Center, Indianapolis, Indiana 46285

    1 shared publication
  • AnnCatherine M. Downing

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, Merck Research Laboratories, West Point, Pennsylvania 19486, Lilly-NUS Centre for Clinical Pharmacology Pte, Ltd., Singapore 117597, and California Clinical Trials, Glendale, California 91206

    1 shared publication

Latest Publications

  • Novel prodrug PRX-P4-003, selectively activated by gut enzymes, may reduce the risk of iatrogenic addiction and abuse

    by Sandeep T. Patil, Ron H. Bihovsky, Steven A. Smith, William Z. Potter, Valentino J. Stella


  • Estimating the Statistical Significance of Peptide Identifications from Shotgun Proteomics Experiments

    by Richard E. Higgs, Michael D. Knierman, Angela Bonner Freeman, Lawrence M. Gelbert, Sandeep T. Patil, John E. Hale

    We present a wrapper-based approach to estimate and control the false discovery rate for peptide identifications using the outputs from multiple commercially available MS/MS search engines. Features of the approach include the flexibility to combine output from multiple search engines with sequence and spectral derived features in a flexible classification model to produce a score associated with correct peptide identifications. This classification model score from a reversed database search is taken as the null distribution for estimating p-values and false discovery rates using a simple and established statistical procedure. Results from 10 analyses of rat sera on an LTQ-FT mass spectrometer indicate that the method is well calibrated for controlling the proportion of false positives in a set of reported peptide identifications while correctly identifying more peptides than rule-based methods using one search engine alone.


  • Identifying Pharmacodynamic Protein Markers of Centrally Active Drugs in Humans: A Pilot Study in a Novel Clinical Model

    by Sandeep T. Patil, Richard E. Higgs, John E. Brandt, Michael D. Knierman, Valentina Gelfanova, Jon P. Butler, AnnCatherine M. Downing, Jill Dorocke, Robert A. Dean, William Z. Potter, et al.

    Recognizing specific protein changes in response to drug administration in humans has the potential for significant utility in clinical research. In spite of this, many methodological and practical questions related to assessing such changes are unanswered. We conducted a series of clinical studies to assess the feasibility of measuring changes in proteins related to drug administration using a mass-spectrometry proteomics technique capable of quantifying hundreds of proteins simultaneously in cerebrospinal fluid (CSF) and plasma. Initially, the normal variability of proteins in these compartments was characterized in 16 healthy volunteers over a 2-week period. Drug-associated changes were subsequently assessed in the plasma and CSF proteomes of 11 subjects given atomoxetine, which served as a selective, centrally active probe to test the model. Protein levels in the CSF and plasma were unchanged between visits in the normal variability study. In contrast, statistically significant changes were detected in the CSF protein pattern after drug treatment. These studies suggest that identification of changes in the CSF proteome associated with the administration of centrally active drugs is feasible, and may be of value in the development of new drugs, as well as broader clinical research. Keywords: Proteomics • CSF • healthy volunteers • pharmacoproteomics • biomarkers • drug development • CNS • mass spectrometry • norepinephrine • DHPG


  • Platelet lipid(s) bound to albumin increases endothelial electrical resistance: mimicked by LPA

    by Fred L. Minnear, Sandeep Patil, Donald Bell, Jonathan P. Gainor, Christine A. Morton

    The objectives were to determine whether the permeability-decreasing activity of platelet-conditioned medium (PCM) is associated with a lipid bound to albumin and whether lysophosphatidic acid (LPA) is present in the PCM. A decrease in permeability was assessed by an increase in electrical resistance across endothelial cell monolayers derived from bovine pulmonary arteries and microvessels. The Sephacryl S-200 fraction of PCM that contained albumin, the albumin immunoprecipitate from the PCM, and the methanol extract from the albumin immunoprecipitate all increased endothelial electrical resistance. Increased electrical resistance induced by PCM was not abolished by boiling and was mimicked by 1-oleoyl-LPA and 1-palmitoyl-LPA. Analysis of a methanol-chloroform extract of one sample of PCM by electrospray mass spectrometry revealed many fatty acids, ceramide, diacylglycerol, phosphatidic acid, and palmitoyl-LPA, but analysis of a second sample of PCM and the methanol extract of its albumin immunoprecipitate revealed no LPA, only lipids. These findings indicate that a bioactive lipid(s), possibly LPA, released from platelets and subsequently bound to albumin forms an active complex that decreases endothelial permeability.


  • Protein, not adenosine or adenine nucleotides, mediates platelet decrease in endothelial permeability

    by Sandeep Patil, John E. Kaplan, Fred L. Minnear

    Platelets and platelet-conditioned medium (PCM) decrease endothelial protein permeability in vitro. Adenosine and a >100-kDa protein have previously been implicated as the soluble factors released from platelets that decrease endothelial permeability. The objective of this study was to further investigate the role of adenosine in this platelet response. Measurements of adenosine and its precursor adenine nucleotides by high-performance liquid chromatography were correlated with the assessment of permeability by125I-labeled albumin clearance and electrical resistance across endothelial cell monolayers derived from the bovine pulmonary artery. PCM contained micromolar concentrations of AMP, ADP, and ATP, but adenosine was below detectable levels (≤0.1 μM). Adenosine deaminase, an enzyme that converts adenosine to inactive inosine, or an adenosine-receptor antagonist did not block the platelet- or PCM-mediated decrease in endothelial permeability. A 3-kDa fraction that contained much reduced levels of AMP and ADP significantly decreased permeability. This activity of PCM was sensitive to insoluble trypsin. This study rules out adenosine and adenine nucleotides as primary factors in the platelet-induced decrease in endothelial permeability and suggests that the active factor is a protein.